Surprised if this stock does not pop well over $8 next few days. The market cap is still very low for a company that should get approved a drug to treat difficult to treat MRSA patients. Even if a forecast sales of just $200 Million per year would rate a market cap of 5x sales for a biotech company at $1 Billion or so MC, but likely those sales #s would be raised higher. Anyone?
might add that their drug is the only bactericidal which kills rather than slows bacteria down like all it's competitors. This will help prevent tolerances as have become an issue with current non effective bacteriostatic antibiotics